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aBstract
Background. Prostate cancer is one of the most common-
ly diagnosed malignancies among males worldwide. In this 
study, overall and age-specific incidence and mortality 
trends are analyzed in order to present the past and current 
epidemiological situation of the disease in Navarre (Spain).
Methods. Population-based incidence data from the 1975-
2010 period, provided by the Cancer Registry of Navarre 
and prostate cancer specific mortality data for 1975-2013, 
provided by the Spanish Statistical Office, were used in the 
analysis. Age-standardized incidence and mortality rates, 
change-points and annual percentage changes (APC) were 
estimated by joinpoint regression analysis. One-dimension-
al P-spline models were used to estimate projections up to 
2016.
results. Considerable increases of cancer incidence rates 
in men aged 45-74 years were observed, with APC of +4.5% 
(p<0.001), +9.5% (p<0.001) and +2.4% (p<0.05) in the 1975-
1990, 1990-2000 and 2000-2010 periods, respectively. In the 
older than 74 age-group, an increase of incidence rates in 
the 1975-1999 period was registered (APC +3.3%, p<0.001), 
followed by a significant decrease up to 2010 (APC -4.0%, 
p<0.01). Mortality rates rose until 1995 (APC +2.2%, p<0.001) 
whereas a decline occurred afterwards up to 2013 (APC 
-3.4%, p<0.001).
conclusion. Even though overall prostate cancer incidence 
rates seem to have stabilized in 2002-2010 in Navarra, trends 
were different by age groups: increased in men 45-74 years 
old and decreased in the 75+ year age-group. A decline in 
mortality rates was observed in both age groups since about 
1995. Changes in the use of prostate specific antigen test for 
screening in oncoming years could affect future prostate 
cancer trends.
Keywords. Prostate Cancer. Incidence. Mortality. Trends. 
Predictions.
resuMen
Fundamento. A nivel mundial, el cáncer de próstata es uno 
de los tumores malignos más comúnmente diagnosticados 
en los hombres. En este estudio, se analizan las tendencias 
de la incidencia y mortalidad de cáncer de próstata, global 
y por grupos de edad, para mostrar la situación epidemioló-
gica pasada y actual de la enfermedad en Navarra (España).
Método. Para el estudio se utilizaron los casos incidentes 
diagnosticados entre 1975 y 2010, y las muertes observadas 
entre 1975 y 2013. Los datos fueron proporcionados por el 
Registro de Cáncer de Navarra y el Instituto Nacional de Esta-
dística respectivamente. Se calcularon las tasas de incidencia 
y mortalidad estandarizadas por edad, los puntos de cambio 
y el porcentaje de cambio anual (PCA) mediante modelos de 
regresión de joinpoint. Se usaron modelos unidimensionales 
de P-splines para estimar proyecciones hasta 2016.
resultados. Se observó un considerable incremento en las 
tasas de incidencia de cáncer de próstata en hombres de 
45-74 años, con PCA de +4,5% (p<0,001), +9,5% (p<0,001) y 
+2,4% (p<0,05) en los periodos 1975-1990, 1990-2000 y 2000-
2010, respectivamente. En el grupo de mayores de 74 se 
registró un aumento de incidencia en el período 1975-1999 
(PCA +3,3%, p<0,001), seguido de una disminución significa-
tiva hasta 2010 (PCA -4,0%, p<0,01). Las tasas de mortalidad 
aumentaron hasta 1995 (PCA +2,2%, p<0,001), mientras que 
descendieron en el periodo 1995-2013 (PCA -3.4%, p<0,001).
conclusión. Aunque las tasas globales de incidencia de 
cáncer de próstata parecen estabilizarse en 2002-2010 en 
Navarra, las tendencias fueron diferentes según los grupos 
de edad, aumentando en los hombres de 45-74 años y dismi-
nuyendo en el grupo de mayores de 74 años. Se observó una 
disminución en las tasas de mortalidad en ambos grupos de 
edad desde 1995. Cambios en el uso del antígeno prostático 
específico para cribado en los próximos años podrían afec-
tar las futuras tendencias del cáncer de próstata.
Palabras clave. Cáncer de Próstata. Incidencia. Mortalidad. 
Estimaciones. Tendencias.
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introDuction
According to the last estimations pro-
vided by the International Agency for Re-
search on Cancer (IARC), prostate cancer 
was the second most common cancer 
diagnosed in men worldwide in 2012, ac-
counting for 15% of the cancer cases. Al-
most 70% of them occurred in developed 
regions, where prostate specific antigen 
(PSA) testing and subsequent biopsy are 
widespread1. The PSA testing has a big 
effect on incidence rates and therefore 
the rates can vary among different coun-
tries according to the level of PSA imple-
mentation. Prostate cancer incidence has 
increased in recent decades in Europe2. 
As far as mortality is concerned, 307,000 
deaths were estimated worldwide in 2012, 
placing prostate cancer as the fifth leading 
cause of death from cancer in men (6.6% of 
the total men deaths). The mortality rates 
are less variable among different regions 
worldwide3.
As in other European countries, pros-
tate cancer is the most frequent cancer in 
Spain among men. In 2015, according to 
the last estimations provided by Galcerán 
and col4, 33,370 cases were diagnosed in 
Spain. Prostate cancer mortality is placed 
as a third cause of death by cancer in men 
after lung and large bowel cancer4,5.
The objective of this study is to pro-
vide an in-depth description of trends of 
prostate cancer in Navarra. To do so, the 
most up-to-date population-based inci-
dence and mortality data were used. The 
study is focused on the observed overall 
and age-specific incidence and mortality 
trends. Additionally, projections of the in-
cidence and mortality rates are provided 
up to 2016 as an updated indicator of the 
burden of this cancer in Navarra.
MethoDs
Data on the incidence of invasive pros-
tate cancer were obtained from the popu-
lation-based Cancer Registry of Navarra, a 
region in northern Spain with a population 
of approximately 640,000 inhabitants in 
2010 in which almost 50% were men. We 
used the most up-to-date prostate cancer 
incidence data available in the cancer reg-
istry, covering the period 1975-2010. The 
Navarra Cancer Registry uses multiple 
sources of information on cancer, includ-
ing pathology laboratories, hospitals and 
death certificates. Mortality data from 1975 
to 2013 were provided by the Spanish Sta-
tistical Office6. Population data by 5-year 
age groups and gender were obtained from 
the Statistical Institute of Navarra7.
A brief descriptive analysis is provided 
computing the total number of cases, the 
average number of cases per year with the 
standard deviation and the maximum and 
minimum number for the first and last ten 
year period of study for the total popula-
tion and for 45-74 and older than 74 (75+) 
year age-groups (results for age-group be-
low 45 years were not provided in the de-
scriptive analysis due to the small number 
of cases).
Annual age-standardized incidence and 
mortality rates were calculated by the di-
rect method using the new revised Euro-
pean Standard Population 20138. Trends 
in incidence and mortality rates were ana-
lyzed and change-points and annual per-
centage changes (APC) were estimated by 
joinpoint regression analysis using Join-
point Trend Analysis Software 4.2.0.29,10. 
The estimates and p-values for the annual 
percentage changes (APC) were estimated 
as 100*(exp(β)-1), where β is the slope of 
the following log-linear regression mod-
el ln(y)= β0 + β1*t, where t is the variable 
time. The p-value of the APC comes from a 
two-sided test for regression slope which 
is based on a t distribution9. These analy-
ses were carried out for the whole popula-
tion and for 45-74 year and 75+ year age-
groups.
One-dimensional P-spline models were 
used to estimate projections of the pros-
tate cancer incidence and mortality rates 
up to 2016. In order to obtain the best 
estimations, the models were fitted in dif-
ferent periods: 1989-2010, 1990-2010, 1991-
2010, and so on. Then, a validation process 
was carried out, in order to assess the pre-
dictive performances of models. In this 
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process, the mean absolute relative bias 
(MARB) was computed for each fitting. 
This measure indicates which time period 
is the best to provide the best predictions. 
Values close to cero indicate good perfor-
mance of the model11. The MARB indicated 
that 1999-2010 period was the best to pre-
dict incidence rates and 1996-2013 period 
was the best to predict mortality rates. 
The mean MARB values for incidence and 
mortality predictions where 0.0484 and 
0.0759.
results
A total of 7,707 incident cases of inva-
sive prostate cancer were recorded in the 
twenty-five year period and 1,629 prostate 
cancer deaths occurred in the twenty-eight 
year period analysed. Incidence and mortal-
ity in the first and the last ten years of the 
study period are shown in table 1. The an-
nual number of incident cases markedly in-
creased between these two periods from 83 
to 377. By age-groups the absolute number 
table 1. Prostate cancer incidence and mortality in the first and last ten years of the study period for 
the total population and by age-groups in Navarra
Descriptive Analysis Incidence 1975-1985
Mortality 
 1975-1985
Incidence 
 2000-2010
Mortality 
2000-2013
Total Population
Total number 915 493 4149 1138
Annual average
(SD)
83
(22)
45
(10)
377
(38)
81
(8)
Maximum number of 
cases (year)
119
(1985)
69
(1985)
457
(2008)
99
(2000)
Minimum number of 
cases (year)
50
(1975)
33
(1975)
331
(2006)
66
(2010)
Age-standardized ratesa 
(95% CI)
68
(63-73)
41
(37-45)
161
(154-169)
39
(36-43)
By Age-group
45-74 Total number 461 179 2730 273
Annual average
(SD)
42
(10)
16
(3)
248
(40)
20
(6)
Maximum number of 
cases (year)
56
(1985)
21
(1983)
322
(2008)
30
(2000)
Minimum number of 
cases (year)
28
(1975)
13
(1977)
193
(2002)
11
(2010)
Age-standardized 
truncated ratesa (95% CI)
69
(64-74)
27
(24-30)
278
(298-288)
22
(19-25)
75 + Total number 453 312 1418 865
Annual average  
(SD)
41
(13)
28
(9)
129
(12)
61
(5)
Maximum number of 
cases (year)
63
(1985)
50
(1985)
154
(2002)
70
(2008)
Minimum number of 
cases (year)
21
(1975)
18
(1975)
111
(2006)
53
(2007)
Age-standardized 
truncated ratesa (95% CI)
471
(458-483)
345
(335-356)
649
(634-664)
334
(324-343)
SD: standard deviation; a: annual mean; 95% CI: confidence interval; 75+: 75 years or older
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of incident cases rose from 42 to 248 in men 
45-74 years old and from 41 to 129 in men 
aged 75+. Similarly, an increase in the abso-
lute number of prostate cancer deaths was 
observed between the two periods.
Trends in age-standardized incidence 
and mortality rates for the whole popula-
tion are shown in figure 1. Prostate cancer 
incidence rates increased by 4.1% annually 
between 1975 and 2002 (p<0.001) followed 
by a stabilization of rates until 2010 (APC 
+0.7%, p=0.726); therefore, a change point 
in incidence was estimated in 2002. On the 
other hand, the mortality rates showed an 
increase of 2.2% (p<0.001) per year up to 
1995, while a decreasing trend (APC -3.4%, 
p<0.001) was observed up to 2013.
Age-specific incidence rate trends for 
45-74 and 75+ age-groups are shown in 
figure 2. An increase in incidence was ob-
served in the 45-74 age-group over the 
studied period. More precisely, incidence 
rates increased by 4.5% annually from 1975 
to 1990 (p<0.001), then by 9,6% per year up 
to 2000 (p<0.001), followed by a less pro-
nounced increase up to 2010 (APC +2.4%, 
Figure 1. Trends and change points in age-standardized incidence and mortality rates of prostate cancer 
in Navarra.
Figure 2. Trends and change points in age-standardized incidence and mortality rates of prostate cancer 
by age-groups (45-74 and 75 or older) in Navarra.
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p=0.023). In the 75+ age-group, an increase 
of rates was observed between 1975 and 
1999 (APC +3.3%, p<0.001), followed by a 
significant decrease (APC -4.0%, p<0.01). 
Mortality trends were quite similar in the 
two age-groups. The mortality rates for the 
45-74 age-group increased up to 1994 (2.9% 
per year, p<0.01), afterwards a significant 
decline was observed up to 2013 (APC 
-4.7%, p<0.001). In the 75+ age-group mor-
tality rates increased up to 1995 (2.5% per 
year, p<0.001) and then declined up to 2013 
(APC -3.6% per year, p<0.001).
Estimated projections for prostate can-
cer incidence and mortality up to 2016 
based on one-dimensional P-spline models 
were represented in figure 3. It is estimated 
a slight increase of incidence rates while 
the reduction of mortality would have con-
tinued up to 2016.
Discussion
In this study, prostate cancer inci-
dence and mortality trends were analyzed 
throughout a large period in Navarra. In re-
cent years, even though overall incidence 
rates stabilized from 2002 to 2010, trends 
were different between the two age groups 
Figure 3. Projections of prostate cancer incidence (A) and mortality (B) rates up to 2016 and their 
corresponding 95% prediction intervals (dashed lines).
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analyzed: rates increased in 45-74 years old 
age-group and decreased in the older age-
group. A decline in mortality was observed 
in both age groups since about 1995.
Overall changes in incidence and mor-
tality observed in Navarra are similar to 
those reported in Spain and other Europe-
an countries5,12-14. In Spain, incidence rates 
increased by 1.3% per annum from 1975 
to 1990, and even more sharply thereafter 
(7.3% per annum) up to 200413. The sharp 
rise in incidence after the early 1990s ob-
served also in countries such as the Unit-
ed States and other European countries 
coincided with the introduction of PSA 
testing15-18. Some authors have suggested 
that the increase of incidence may also 
be attributed to the more frequent use of 
transurethral resection of the prostate and 
invasive diagnostic procedures such as 
random biopsies16.
An outstanding finding in Navarra inci-
dence trends, not reported previously in 
Spain, is the decrease of the cancer inci-
dence observed in men 75+ years old. This 
decline in the incidence has been observed 
in men older than 80 years in the United 
Kingdom19, as well as in the United States20. 
In this last country, a recent study showed 
a decline in the incidence not only in the 
older but also in younger age groups since 
2011, and according to the authors this de-
crease could be related to the decreased 
PSA screening after the publication of 
the results from two large clinical trials: 
the prostate, lung, colorectal and ovarian 
(PLCO) cancer screening trial and the Eu-
ropean randomized study of screening for 
prostate cancer (ERSPC)21.
Several authors have discussed about 
different changes in care of prostate cancer 
patients and their contribution in the de-
cline of prostate cancer mortality: increase 
in the use of higher-definition computed 
tomography and ultrasonography for a bet-
ter diagnosis and staging, more refined sur-
gical approaches, introduction of antian-
drogen therapies, chemotherapy and new 
modes of radiation treatment, and the use 
of PSA for diagnosis and monitoring to de-
tect locally recurrent or metastatic disease 
before it becomes symptomatic22,23.
Based on the observed period, inci-
dence rates are projected up to 2016. How-
ever, since the prostate cancer incidence is 
very sensitive to PSA screening, changes in 
screening practices could affect markedly 
these predictions. Currently, the Sociedad 
Española de Medicina Familiar y Comunitar-
ia (semFYC), the Canadian Task Force on 
Preventive Health, the UK National Screen-
ing Committee and the US Preventive Ser-
vices Task Force, among other scientific 
institutions, do not recommend PSA-based 
systematic screening for prostate cancer 
in asymptomatic population. These recom-
mendations are supported by studies meas-
uring pros and cons of early detection and 
subsequent treatment of localized prostate 
cancer. Additionally, there are no evidenc-
es indicating that prostate cancer patients 
diagnosed by screening have better out-
comes than those diagnosed from clinical 
symptoms. Furthermore, it should be taken 
into account the important risks associated 
with PSA screening, including the risks of 
overdiagnosis and overtreatment24.
In conclusion, overall prostate cancer 
incidence rates seem to have stabilized in 
2002-2010 in Navarra, however, trends were 
different by age groups: increased in men 
45-74 years old whereas decreased in the 
75+ year age-group. A decline in mortali-
ty rates was observed in both age groups 
since about 1995. Changes in the use of PSA 
test for screening in oncoming years could 
affect future prostate cancer trends.
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